Europe Molecular Diagnostics Market Analysis, Segmentation, and Growth Outlook Report By 2024

Europe Molecular Diagnostics Market Analysis,
Segmentation, and Growth Outlook Report By 2024
“The Europe Molecular Diagnostics Market was appreciated at US$ 1750.0 million in the
year 2015 and is estimated to reach USD 4.0 billion by 2024. It is anticipated to develop at
a substantial CAGR for the duration of the prediction. Europe is a technologically
advanced region.”
The Europe Molecular Diagnostics Market was appreciated at US$ 1750.0 million in the year 2015 and is estimated to
reach USD 4.0 billion by 2024. It is anticipated to develop at a substantial CAGR for the duration of the prediction.
Europe is a technologically advanced region. Categorized by a huge number of elderly inhabitants, the area has observed
a steady growth due to prevalence of long-lasting sicknesses, for instance non-infectious sicknesses, diabetes, and
cardiovascular sicknesses.
The Europe molecular diagnostics industry on the source of Type of Application Pharmacogenomics, Neurological
Disease, Microbiology, Cardiovascular Disease, Infectious Diseases. The subdivision of Infectious Diseases held the
biggest stake of the market, due to the greater occurrence of HIV. It generated the highest income during the year 2015.
Furthermore, the progress of new-fangled diagnostics examinations in the range of infectious diseases is emphasizing
the development of this market.
The Europe molecular diagnostics market on the source of Type of Technology could span Transcription-mediated
Amplification, Mass Spectrometry, Isothermal Nucleic Acid Amplification Technology [INAAT], PCR, [Multiplex PCR],
Sequencing, Chips & Microarrays, and In Situ Hybridization. The subdivision of PCR detained the biggest stake of the
market nearby the year 2015. It could be credited mostly to the growing use of molecular diagnostics in the arena of
pharmacogenomics and the increasing practice of multiplex PCR skills.
The Europe molecular diagnostics industry on the source of Type of Test Location could span Central Laboratories, Point
of Care, Self-Test. The subdivision of Point of Care [PoC] is expected to develop at a profitable CAGR above the
prediction period. The increasing demand for speedy analysis together with the readiness of freshly developed skill of
Point of Care to observe the reactions of medicine, in patients through cardiac sicknesses, will subsidize in the direction
of the progress of this subdivision.
Request Sample Copy of This Market Research @
https://www.millioninsights.com/industry-reports/europe-molecular-diagnostics-market/request-sample

The Europe molecular diagnostics market on the source of Type of Product could span Reagents, Instruments, and
additional products. The additional products comprise software programs and the services. These are supportive in the
administration of the instrumentation procedure. The division was ruled by the subdivision of reagents by means of
above 50.0% stake during the year 2015. Reagents comprise SDS, salts, heparin or dextran sulphate, and form amide.
These are usually utilized in execution of in-situ hybridization examination.
The subdivision of reagents is likewise projected to boost at a dual digit CAGR above the prediction period. Increasing
practice of methods including fluorescence in situ hybridization is contributing to the additional development of this
subdivision. The Europe molecular diagnostics market on the source of Area with respect to Trades in terms of intake,
Profits, Market stake and Development percentage in these areas, for the duration of the prediction could span Italy,
Spain, Germany, France, and the U.K.
By the source of geography, Germany was the biggest market in Europe during the year 2015. It was responsible for a
market stake of more than 20.0% of the general market for molecular diagnostics. Growing technical improvements and
the base of ageing residents in the arena of molecular diagnostics are the most important factors for the lucrative
progress of the market.
Similarly, the UK offers a developing market, in this arena, by means of a well-paid development above the forecast
period of prediction. Reasons backing speedy progress of the market consist of existence of a strong substructure of
healthcare, gushing per head earnings, and the growing stages of alertness between people for the timely identification
of deadly sicknesses, which includes HIV, and Cancer.
The statement revises Trades in terms of intake of Europe Molecular Diagnostics in the market; particularly in Italy,
Spain, Germany, France, and the U.K. It concentrates on the topmost companies operating in these regions. Some of the
important companies operating in the field are Thermo Fisher Scientific, Inc., Eppendorf AG, QIAGEN N.V, Bio-Rad
Laboratories, Inc., Becton Dickinson and Company, Agilent Technologies, Inc., PerkinElmer, Inc., Danaher Corporation, F.
Hoffmann-La Roche Ltd., Tecan Group Ltd., Illumina, Inc., Cepheid Inc., Abbott Laboratories, Hologic Inc., Myriad
Genetics, Novartis A G, and Gen-probe. Additional notable companies operating in the field are-bioMérieux SA, Dako,
Johnson and Johnson, Bayer AG, Alere, Inc., and Siemens Healthcare GmbH.
Market Segment:
Europe Molecular Diagnostics Product Outlook (Market Revenue in USD Million, 2013 - 2024)
• Instruments
• Reagents
• Others
Europe Molecular Diagnostics Test Location Outlook (Market Revenue in USD Million, 2013 - 2024)
• Point of care
• Self-testing or OTC
• Central laboratories
Europe Molecular Diagnostics Technology Outlook (Market Revenue in USD Million, 2013 - 2024)
• PCR

• In-situ hybridization
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Chips and microarrays
• Mass spectrometry
• Sequencing
• Transcription-mediated amplification
• Others
Europe Molecular Diagnostics PCR, by segments Outlook (Market Revenue in USD Million, 2013 - 2024)
• Multiplex PCR
• Others
Europe Molecular Diagnostics Application Outlook (Market Revenue in USD Million, 2013 - 2024)
• Oncology
• Pharmacogenomics
• Infectious diseases
• Genetic testing
• Neurological diseases
• Cardiovascular diseases
• Microbiology
• Others
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/europe-molecular-diagnostics-market
Europe Molecular Diagnostics Oncology, By Application Outlook (Market Revenue in USD Million, 2013 - 2024)
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Cervical Cancer
• Kidney Cancer
• Liver Cancer
• Blood Cancer
• Lung Cancer
• Others
Europe Molecular Diagnostics Infectious Disease, By Application Outlook (Market Revenue in USD Million, 2013 -
2024)
• Methicillin-resistant Staphylococcus aureus (MRSA)
• Clostridium difficile
• Vancomycin-resistant enterococci
• Carbapenem-resistant bacteria testing
• Flu
• Respiratory syncytial virus (RSV)
• Candida
• Tuberculosis and drug-resistant TB

• Meningitis
• Gastro-intestinal panel testing
• Chlamydia
• Gonorrhea
• HIV
• Hepatitis C
• Hepatitis B
• Other
Europe Molecular Diagnostics Genetic Testing, By Application Outlook (Market Revenue in USD Million, 2013 - 2024)
• Newborn screening
• Predictive and presymptomatic testing
• Others
Europe Molecular Diagnostics Country Outlook (Market Revenue in USD Million, 2013 - 2024)
• UK
• Germany
• France
• Spain
• Italy
• Belgium
• Switzerland
• Netherlands
• Poland
• Austria
• Greece
• Sweden
• Turkey
• Finland
See More Reports of this Category by Million Insights @
https://www.millioninsights.com/industry/healthcare

Get in touch
At Million Insights, we work with the aim to reach the highest levels of customer satisfaction.
Our representatives strive to understand diverse client requirements and cater to the same with
the most innovative and functional solutions.
Contact Person:
Ryan Manuel
Research Support Specialist, USA
Email: ryan@millioninsights.com
Global Headquarters
Million Insights
Felton Office Plaza 6265 Highway 9 Felton, California 95018, United States
Phone: 1-408-610-2300
Email: sales@millioninsights.com
Asia Pacific
Million Insights
Office No. 302, 3rd Floor, Manikchand Galleria, Model Colony, Shivaji Nagar, Pune, MH, 411016
India
Phone: 91-20-65300184